Literature DB >> 17071494

Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population.

W Y Au1, A Fung, K F Wong, C H Chan, R Liang.   

Abstract

The -308 GA promoter polymorphism of tumor necrosis factor alpha (TNFalpha) has been reported to be associated with an increased risk of lymphoid malignancies in Caucasians. We studied the incidence and prognostic significance of this polymorphism in Chinese patients with plasma cell myeloma (PCM), chronic lymphocytic leukemia (CLL) and lymphomas. Despite a far lower incidence of PCM and CLL in the Chinese population compared with Caucasians, the rates of TNFalpha-308A were similar to those in Caucasians, both in the study and control populations. Similarly, there was no increased rate of TNFalpha-308A in all the lymphomas studied, irrespective of lineage. However, TNFalpha-308A is significantly associated with female CLL cases and confers a strong negative prognostic impact for Chinese CLL. These argue for a possible biological role for increased TNFalpha production in CLL progression in low-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071494     DOI: 10.1080/10428190600758645

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia.

Authors:  Mustafa Pehlivan; Handan Haydaroglu Sahin; Sacide Pehlivan; Kursat Ozdilli; Leylagul Kaynar; Fatma Savran Oguz; Tugce Sever; Mehmet Yilmaz; Bulent Eser; Yeliz Duvarci Ogret; Cem Kis; Vahap Okan; Mustafa Cetin; Mahmut Carin
Journal:  Genet Test Mol Biomarkers       Date:  2014-05-12

2.  The association between the polymorphisms of TNF-α and non-Hodgkin lymphoma: a meta-analysis.

Authors:  Yong-Qiao He; Jin-Hong Zhu; Shao-Yi Huang; Zhuo Cui; Jing He; Wei-Hua Jia
Journal:  Tumour Biol       Date:  2014-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.